MX2023013046A - Compuestos para direccionar la degradacion de tirosina cinasa de bruton. - Google Patents
Compuestos para direccionar la degradacion de tirosina cinasa de bruton.Info
- Publication number
- MX2023013046A MX2023013046A MX2023013046A MX2023013046A MX2023013046A MX 2023013046 A MX2023013046 A MX 2023013046A MX 2023013046 A MX2023013046 A MX 2023013046A MX 2023013046 A MX2023013046 A MX 2023013046A MX 2023013046 A MX2023013046 A MX 2023013046A
- Authority
- MX
- Mexico
- Prior art keywords
- btk
- compounds
- degradation
- dsm
- linker
- Prior art date
Links
- 230000015556 catabolic process Effects 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000006731 degradation reaction Methods 0.000 title abstract 4
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción se relaciona con compuestos de Fórmula (A): BTK-L-DSM (A) o una sal farmacéuticamente aceptable de estos, donde DSM es un resto de señalización de degradación que se une, de forma covalente, al enlazador L, L es un enlazador que une, de forma covalente, BTK a DSM, y BTK es un resto de unión a Btk representado por la Fórmula (I) o la Fórmula (II) que se une, de forma covalente, al enlazador L: en la que todas las variables son como se definen en la solicitud. Los compuestos o sales farmacéuticamente aceptables de estos son capaces de activar la ubiquitinación selectiva de proteínas Btk mediante las vías de ubiquitina-proteasoma (UPP) y causar la degradación de proteínas Btk. La presente descripción también proporciona métodos para tratar trastornos que responden a la modulación de la actividad de Btk y/o la degradación de Btk con al menos un compuesto descrito en la presente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184439P | 2021-05-05 | 2021-05-05 | |
| PCT/US2022/027888 WO2022235945A1 (en) | 2021-05-05 | 2022-05-05 | Compounds for targeting degradation of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013046A true MX2023013046A (es) | 2023-12-15 |
Family
ID=82115630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013046A MX2023013046A (es) | 2021-05-05 | 2022-05-05 | Compuestos para direccionar la degradacion de tirosina cinasa de bruton. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240287076A1 (es) |
| EP (1) | EP4333899A1 (es) |
| JP (1) | JP2024519496A (es) |
| KR (1) | KR20240017814A (es) |
| CN (1) | CN117580592A (es) |
| AR (1) | AR125768A1 (es) |
| AU (1) | AU2022268977A1 (es) |
| BR (1) | BR112023023065A2 (es) |
| CA (1) | CA3217417A1 (es) |
| CL (1) | CL2023003258A1 (es) |
| CO (1) | CO2023016743A2 (es) |
| IL (1) | IL308219A (es) |
| MX (1) | MX2023013046A (es) |
| TW (1) | TW202309039A (es) |
| UY (1) | UY39756A (es) |
| WO (1) | WO2022235945A1 (es) |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| KR20240038809A (ko) | 2014-04-14 | 2024-03-25 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| CN107257800B (zh) | 2014-12-23 | 2020-06-30 | 达纳-法伯癌症研究所股份有限公司 | 通过双功能分子诱导靶蛋白降解的方法 |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| CN108601764A (zh) | 2015-03-18 | 2018-09-28 | 阿尔维纳斯股份有限公司 | 用于靶蛋白的增强降解的化合物和方法 |
| ES2862469T3 (es) | 2015-06-04 | 2021-10-07 | Arvinas Operations Inc | Moduladores de proteólisis a base de imidas y métodos de uso asociados |
| EP3302482A4 (en) | 2015-06-05 | 2018-12-19 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| KR20180035828A (ko) | 2015-07-10 | 2018-04-06 | 아비나스 인코포레이티드 | 단백질 분해의 mdm2계 조절인자 및 관련된 이용 방법 |
| WO2017011590A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| UA123786C2 (uk) | 2016-04-06 | 2021-06-02 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Деструктори білка mdm2 |
| EP3442976B1 (en) | 2016-04-12 | 2022-07-20 | The Regents of The University of Michigan | Bet protein degraders |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| US20180072711A1 (en) | 2016-09-15 | 2018-03-15 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| PL3660004T3 (pl) | 2016-10-11 | 2023-10-02 | Arvinas Operations, Inc. | Związki i sposoby do ukierunkowanej degradacji receptora androgenowego |
| CN110234646A (zh) | 2016-11-01 | 2019-09-13 | 阿尔维纳斯股份有限公司 | 靶向PROTAC的Tau蛋白及相关使用方法 |
| US10647698B2 (en) | 2016-12-01 | 2020-05-12 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| EP3558994A4 (en) | 2016-12-23 | 2021-05-12 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| UY37559A (es) * | 2017-01-06 | 2018-05-31 | Pharmacyclics Llc | Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton |
| AU2018211975B2 (en) | 2017-01-26 | 2022-05-26 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| KR20190116315A (ko) | 2017-01-31 | 2019-10-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레블론 리간드 및 이를 포함하는 이작용성 화합물 |
| US20180353501A1 (en) | 2017-06-09 | 2018-12-13 | Arvinas, Inc. | Modulators of proteolysis and associated methods of use |
| WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS |
| CN111212835A (zh) | 2017-07-28 | 2020-05-29 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| EP4166557A1 (en) * | 2018-03-26 | 2023-04-19 | Novartis AG | Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| JP7252972B2 (ja) * | 2018-03-26 | 2023-04-05 | ノバルティス アーゲー | ３－ヒドロキシ－Ｎ－（３－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）フェニル）ピロリジン－１－カルボキサミド誘導体 |
| CA3094305A1 (en) | 2018-04-01 | 2019-10-10 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| CN118480030A (zh) | 2018-04-13 | 2024-08-13 | 阿尔维纳斯运营股份有限公司 | 小脑蛋白配体和包括其的双官能化合物 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| CN113557235A (zh) | 2019-03-06 | 2021-10-26 | C4医药公司 | 用于药物治疗的杂环化合物 |
| SG11202109024YA (en) | 2019-04-12 | 2021-09-29 | C4 Therapeutics Inc | Tricyclic degraders of ikaros and aiolos |
| JP2022547716A (ja) * | 2019-09-16 | 2022-11-15 | ノバルティス アーゲー | 二機能性分解誘導薬及びそれらの使用方法 |
| US20220411429A1 (en) * | 2019-10-30 | 2022-12-29 | Biogen Ma Inc. | Condensed pyridazine or pyrimidine as btk inhibitors |
| US20230025892A1 (en) * | 2019-10-30 | 2023-01-26 | Biogen Ma Inc. | Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase |
| CN116194453A (zh) | 2019-12-20 | 2023-05-30 | 卡里科生命科学有限责任公司 | 蛋白质酪氨酸磷酸酶降解剂及其使用方法 |
| MX2022013407A (es) * | 2020-04-30 | 2022-11-14 | Beigene Ltd | Degradacion de la tirosina cinasa de bruton (btk) mediante conjugacion de inhibidores btk con ligando de ligasa e3 y metodos de uso. |
-
2022
- 2022-05-05 AU AU2022268977A patent/AU2022268977A1/en active Pending
- 2022-05-05 KR KR1020237041952A patent/KR20240017814A/ko unknown
- 2022-05-05 CN CN202280047793.5A patent/CN117580592A/zh active Pending
- 2022-05-05 US US18/289,438 patent/US20240287076A1/en active Pending
- 2022-05-05 IL IL308219A patent/IL308219A/en unknown
- 2022-05-05 WO PCT/US2022/027888 patent/WO2022235945A1/en active Application Filing
- 2022-05-05 MX MX2023013046A patent/MX2023013046A/es unknown
- 2022-05-05 TW TW111116998A patent/TW202309039A/zh unknown
- 2022-05-05 CA CA3217417A patent/CA3217417A1/en active Pending
- 2022-05-05 EP EP22731839.1A patent/EP4333899A1/en active Pending
- 2022-05-05 JP JP2023567962A patent/JP2024519496A/ja active Pending
- 2022-05-05 AR ARP220101179A patent/AR125768A1/es unknown
- 2022-05-05 UY UY0001039756A patent/UY39756A/es unknown
- 2022-05-05 BR BR112023023065A patent/BR112023023065A2/pt unknown
-
2023
- 2023-11-02 CL CL2023003258A patent/CL2023003258A1/es unknown
- 2023-12-01 CO CONC2023/0016743A patent/CO2023016743A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240017814A (ko) | 2024-02-08 |
| UY39756A (es) | 2022-11-30 |
| CN117580592A (zh) | 2024-02-20 |
| BR112023023065A2 (pt) | 2024-01-30 |
| CA3217417A1 (en) | 2022-11-10 |
| US20240287076A1 (en) | 2024-08-29 |
| CL2023003258A1 (es) | 2024-05-03 |
| CO2023016743A2 (es) | 2023-12-29 |
| TW202309039A (zh) | 2023-03-01 |
| AR125768A1 (es) | 2023-08-09 |
| WO2022235945A1 (en) | 2022-11-10 |
| JP2024519496A (ja) | 2024-05-14 |
| IL308219A (en) | 2024-01-01 |
| EP4333899A1 (en) | 2024-03-13 |
| AU2022268977A1 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000395A (es) | Compuestos para la degradacion selectiva de las proteinas irak4. | |
| EA200870373A1 (ru) | Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ | |
| ATE343388T1 (de) | Pde-v hemmer zur behandlung von morbus parkinson | |
| DE602004019198D1 (de) | Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege | |
| EA202090987A1 (ru) | Новые пролекарства на основе катехоламина для применения в лечении болезни паркинсона | |
| MY144483A (en) | 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases | |
| DE60026155D1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| EA200802329A1 (ru) | Производные триазола ii | |
| DE60028740D1 (de) | Phthalazinderivate zur behandlung von entzündlicher erkrankungen | |
| DE602004024880D1 (de) | Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten | |
| BRPI0412347A (pt) | 2-aminofenil-4-fenilpiridinas como inibidores de quinase | |
| BG95508A (bg) | 4-бензоил изоксазолови производни | |
| MX2021006951A (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa. | |
| MX2023010303A (es) | Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol. | |
| MX2020008816A (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| IL192287A0 (en) | Pharmaceutical compositions and methods for use | |
| DE69834500D1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
| UA86873C2 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES | |
| MX2023013046A (es) | Compuestos para direccionar la degradacion de tirosina cinasa de bruton. | |
| WO2021076938A8 (en) | Tropolone derivatives and tautomers thereof for iron regulation in animals | |
| ATE192923T1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
| MX2022012404A (es) | Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. | |
| BR0317289A (pt) | Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico | |
| MX2023003446A (es) | Compuesto de pirimidina carboxamida y aplicación del mismo. | |
| ATE315387T1 (de) | Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz |